anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention is directed to novel hepatotropic hepaciviruses isolated in Norway rats (Rattus norvegicus), designated NrHV-1 or RHV-rn-NY01 and NrHV-2 or RHV-rn-NY02, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to antibodies against antigens from NrHV- 1 or NrHV-2 found in Rattus norvegicus. The invention also relates to iRNAs which target nucleic acid sequences of NrHV- 1 or NrHV-2 found in Rattus norvegicus. The invention is related to methods for detecting the presence or absence of NrHV-1 or NrHV-2 found in Rattus norvegicus in an animal. The invention is also related to immunogenic compositions for inducing an immune response against NrHV-1 or NrHV-2 in an animal. The invention is also related to a cell culture system and a laboratory animal to model human hepatitis C virus (HCV).
Process for in vitro production of a culture or cell line infected by a viral strain associated with multiple sclerosis. According to the process, a sample is taken from a person with multiple sclerosis, the sample is cultivated in a medium promoting the growth of infected cells to obtain a culture of primary infected cells. A sample of the primary cell culture or a sub-culture of the latter is then cultivated in series, i.e. by means of successive cultures, in said culture medium to obtain the culture or cell line infected by a multiple sclerosis associated virus. The invention is characterized in that the culture medium further contains a beta anti-interferon antibody or antibody which is directed against an antigenically close molecule. Said antibody plays an inhibiting role in viral expression, has long-lasting expression and propagates the viral strain in the culture or cell line.
Spinal cord injury (SCI) affects ∼500,000 people worldwide annually, with the majority developing chronic neuropathic pain. Following SCI, approximately 60% of these individuals are diagnosed with comorbid mood disorders, while only ∼21% of the general population will experience a mood disorder in their lifetime. We hypothesize that nociceptive and depressive-like dysregulation occurs after SCI and is associated with aberrant macrophage infiltration in segmental pain centers. We completed moderate unilateral C5 spinal cord contusion on LysM-eGFP reporter mice to visualize infiltrating macrophages. At 6-weeks post-SCI, mice exhibit nociceptive and depressive-like dysfunction compared to naïve and sham groups. There were no differences between the sexes, indicating that sex is not a contributing factor driving nociceptive or depressive-like behaviors after SCI. Utilizing hierarchical cluster analysis, we classified mice based on endpoint nociceptive and depressive-like behavior scores. Approximately 59.3% of the SCI mice clustered based on increased paw withdrawal threshold to mechanical stimuli and immobility time in the forced swim test. SCI mice displayed increased myeloid cell presence in the lesion epicenter, ipsilateral C7-8 dorsal horn, and C7-8 DRGs as evidenced by eGFP, CD68, and Iba1 immunostaining when compared to naïve and sham mice. This was further confirmed by SCI-induced alterations in the expression of genes indicative of myeloid cell activation states and their associated secretome in the dorsal horn and dorsal root ganglia. In conclusion, moderate unilateral cervical SCI caused the development of pain-related and depressive-like behaviors in a subset of mice and these behavioral changes are consistent with immune system activation in the segmental pain pathway. PERSPECTIVE: These experiments characterized pain-related and depressive-like behaviors and correlated these changes with the immune response post-SCI. While humanizing the rodent is impossible, the results from this study inform clinical literature to closely examine sex differences reported in humans to better understand the underlying shared etiologies of pain and depressive-like behaviors following central nervous system trauma.
Routine treatment and care interventions will be applied to the patients included in the control group during the procedure. Patients in the control group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level.
The invention provides pET15b-PEP-1-VP3 plasmids, a construction method of the pET15b-PEP-1-VP3 plasmids, a PEP-1-VP3 fusion protein and an expression method of the PEP-1-VP3 fusion protein. Specifically, upstream and downstream primers are designed and are synthesized through PGEX-6P-1/TAT-VP3 plasmids as templates, and are subjected to polymerase chain reaction (PCR) amplification, wherein amplification conditions comprise that an initial denaturation process is carried out at a temperature of 95 DEG C for 1 minute; then follow-up reaction processes are carried out respectively at 95 DEG C for 30 seconds and at 68 DEG C for 3 minutes and repeat for 35 cycles; and finally, a reaction process is carried out at a temperature of 68 DEG C for 30 minutes. PCR products are subjected to low-melting point agarose gel electrophoresis and then are identified. VP3cDNA fragments of 366bp are recovered and purified. Because the expressed PEP-1-VP3 fusion protein exists mainly in a form of an inclusion body, the collected thalli are dissolved in a 50ml of a buffer A and are subjected to thallus and inclusion body ultrasonication processes for 41 minutes under conditions of the power of 400 W, a period of 10 minutes, a time interval of 5 minutes and a temperature of 4 DEG C. A fully broken bacterial liquid is clear, is put into a preparative ultracentrifuge and is treated at rotate speed of 20000rpm at a temperature of 4 DEG C for 10 minutes. The fusion protein exists in a supernatant in a soluble form. The supernatant is slowly added into a Ni<2+>-nitrilotriacetic acid agarose affinity chromatography column. After sample loading, a hybrid combination process is carried out for 3 hours.
PURPOSE: A composition containing Cudrania Tricuspidata extract for suppressing neuraminidase activation and pharmaceutical composition for preventing and treating influenza virus infectious diseases are provided. CONSTITUTION: A composition for suppressing neuraminidase activation contains Cudrania Tricuspidata extract as an active ingredient. The neuraminidase is derived from type A influenza virus, type B influenza virus, type C influenza virus, Clostridium perfringens or human. A Cudrania Tricuspidata fraction is obtained by suspending Cudrania Tricuspidata extract in water, and fractioning with hexane, chloroform and ethyl acetate. A composition for suppressing neuraminidase activation contains a compound of chemical formula 1 as an active ingredient. A pharmaceutical composition for preventing and treating influenza virus infectious disease contains the Cudrania Tricuspidata extract as an active ingredient.
The active substance is released gradually during its transit through the gastrointestinal tract. Slow release (SR) morphine is available in 5, 10, 30, 60, 100 and 200 mg. SR morphine is administered twice a day, usually every twelfth hour.
A method for sensing presence of at least one specified chemical component in a patient's sample gas, associated with a disease (or medical condition), and for associating presence of the disease with presence of the specified chemical component concentration in an identified concentration range. Pattern matching is applied to identify one or more specified components that are present in the sample gas. Measured electrical parameter values (EPVs) for each nanosensor are modeled by constitutive relations dependent on a polynomial of powers of component concentrations. The EPV models are used to estimate component concentrations for the differently functionalized nanosensors. Estimated concentrations are averaged over the sensors to provide an overall concentration value for each surviving specified component. These overall concentration values are compared with concentration ranges associated, to estimate presence or absence of a disease or medical condition.
The invention discloses a traditional Chinese medicine polysaccharide moisturizing and freckle removing mask which comprises a rhizoma anemarrhenae polysaccharide extract, a purslane polysaccharide extract and a plantain seed polysaccharide extract. The polysaccharide extracts of purslane and plantain seed contain not less than 10% of hyaluronic acid. The weight ratio of the rhizoma anemarrhenae polysaccharide extract to the purslane polysaccharide extract to the plantain seed polysaccharide extract is 1: (0.5-2): (0.7-3). The invention also discloses a preparation method of the traditional Chinese medicine polysaccharide mask for moisturizing and removing freckles. The invention discovers that the heat-clearing medicines such as the anemarrhena polysaccharide, the purslane polysaccharide and the plantain seed polysaccharide can make the skin tender, smooth and fine, and especially can lock the moisture of the skin. The three traditional Chinese medicine polysaccharides have high content in medicinal materials, simple extraction method, economic materials, wide medicinal material sources and sticky and thick polysaccharide properties, and are suitable for being prepared into multi-purpose mask products.
The following adverse reactions have been identified during post-approval use of fosaprepitant. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  
Skin and subcutaneous tissue disorders: pruritus, rash, urticaria, Stevens-Johnson syndrome/toxic epidermal necrolysis. [ see Warnings and Precautions (5.2)].   
Immune system disorders: hypersensitivity reactions including anaphylaxis and anaphylactic shock [ see Contraindications (4)Warnings and Precautions (5.2)].   
Nervous system disorders: ifosfamide-induced neurotoxicity reported after fosaprepitant and ifosfamide coadministration.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with abnormal activation of B lymphocytes, which may result in many adverse consequences and even death if not treated actively. Due to the poor therapeutic efficacy and prominent adverse reactions after long-term use of glucocorticoid combined immunosuppressants, the development of targeted drug use for SLE has become a hot area of research for several years. Telitacicept, approved conditionally in China in March 2021, is a biologic agent targeting B lymphocyte stimulator (BLyS）and a proliferating inducing ligand (APRIL) dually for patients with active SLE patients who have not responded to conventional treatment. As another important part of targeted drug use, the research on biomarkers predictive of drug response is also in full swing in the treatment of SLE. The omics technology has unique advantages in screening biomarkers and exploring the mechanism of drug action. The integrated analysis of multi omics can mutually verify and supplement the screening results of a single omics, so as to more systematically and comprehensively analyze the biological molecular functions and regulatory mechanisms. Therefore, this topic selects serum proteomics combined with metabolomics to screen biomarkers for the prediction of the efficacy of Telitacicept, and to explore the mechanism of the difference in the efficacy of Telitacicept, with a view to providing meaningful reference for the exploration of SLE precise treatment.
BACKGROUND: The role of ferroptosis in lupus nephritis (LN) is unclear. This study aimed to explore the effects of ferroptosis-related genes in LN through bioinformatics prediction and experimental validation.
METHODS: Sample data were collected from the GEO dataset and divided into glomeruli and tubulointerstitium. We collected 382 ferroptosis-related genes. The intersection of ferroptosis-related genes with glomeruli and tubulointerstitium data, respectively, was performed. Machine learning methods (including unsupervised cluster typing and random forests) were operated to identify ferroptosis subtyping and ferroptosis important genes in LN. Immune infiltration and functional analysis were performed. The expression of ferroptosis important gene ATF3 was validated in vivo and in vitro.
RESULTS: 6 ferroptosis important genes common to glomeruli and tubulointerstitium were screened, including ATF3, CD44, CYBB, JUN, NCF2, and NNMT. ATF3 decreased in the LN group compared to the Control. Silencing ATF3 mitigated LPS/erastin-induced ferroptosis. Functional analysis showed that ATF3 was markedly enriched in the interferon-gamma-mediated signaling pathway, ECM-receptor interaction, and cell adhesion. In glomeruli, T cells regulatory (Tregs) infiltration decreased and Macrophages M1 levels increased with elevated ATF3 expression. Levels of immune cell infiltration were altered in different ferroptosis subtypes of LN glomeruli and tubulointerstitium.
CONCLUSIONS: Ferroptosis-related ATF3 levels decreased in LN. Inhibition of ATF3 might alleviate LN development by affecting the macrophage M1 and Treg cell infiltration. These implied that ATF3 might be a potential target for developing LN therapeutic strategies.
Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
The invention relates to synthesis of a series of tacrine-caffeic acid hetero-blends and derivatives, a preparation method thereof, medicinal compositions containing them, and their medical application. The structural formula of the tacrine-caffeic acid hetero-blends is shown as formula (I). By changing substituent groups and joints, the inhibitory activity to AChE (acetylcholinesterase) and selectivity to AChE/BuChE (butyrocholinesterase), as well as antioxidant activity can be adjusted. And AChE-induced Abeta (amyloid-beta peptide) aggregation can be inhibited. The tacrine-caffeic acid hetero-blends and derivatives can be prepared into appropriate medicinal dosage forms to treat Alzheimer's disease and other related dementia. The invention belongs to the medical field.
Both early childhood traumatic experiences and current stress increase the risk of suicidal behaviour, in which immune activation might play a role. Previous research suggests an association between mood disorders and P2RX7 gene encoding P2X7 receptors, which stimulate neuroinflammation. We investigated the effect of P2RX7 variation in interaction with early childhood adversities and traumas and recent stressors on lifetime suicide attempts and current suicide risk markers. Overall, 1644 participants completed questionnaires assessing childhood adversities, recent negative life events, and provided information about previous suicide attempts and current suicide risk-related markers, including thoughts of ending their life, death, and hopelessness. Subjects were genotyped for 681 SNPs in the P2RX7 gene, 335 of which passed quality control and were entered into logistic and linear regression models, followed by a clumping procedure to identify clumps of SNPs with a significant main and interaction effect. We identified two significant clumps with a main effect on current suicidal ideation with top SNPs rs641940 and rs1653613. In interaction with childhood trauma, we identified a clump with top SNP psy_rs11615992 and another clump on hopelessness containing rs78473339 as index SNP. Our results suggest that P2RX7 variation may mediate the effect of early childhood adversities and traumas on later emergence of suicide risk.
The safety and effectiveness of HECTOROL capsules were evaluated in two clinical studies in 55 patients with Stage 3 or 4 CKD. Eighty-two percent of the patients were male, the average age was 65 years, 51% were Caucasian, 40% African-American, and the average serum intact PTH level at baseline was 195 pg/mL. While levels of 25-(OH) vitamin D were not evaluated at baseline, retrospective assessments of stored serum revealed that the mean ± SD serum 25-(OH) vitamin D was 19 ± 8 ng/mL (range: <5 to 54 ng/mL) in the study population.

After randomization to two groups, eligible patients underwent an 8-week washout period during which no vitamin D derivatives were administered to either group. Subsequently, one group received HECTOROL capsules and the other placebo during the double-blind period of 24 weeks. The initial dose of HECTOROL capsules was 1 mcg per day. The dosage of HECTOROL capsules was adjusted as necessary by the investigator to reduce intact PTH levels to a target of ≥30% below postwashout baseline. The maximum dosage was limited to 3.5 mcg per day. If at any time during the trial intact PTH fell below 15 pg/mL, HECTOROL capsules were immediately suspended and restarted at a lower dosage the following week.

Decreases in the mean plasma intact PTH from baseline values were calculated using as baseline the average of the last 2 values obtained during the 8-week washout phase. In analyses of pooled data from the two studies, intact PTH levels decreased from baseline by an average of 101 pg/mL in the HECTOROL capsules group and by 4 pg/mL in the placebo group (p<0.001). Twenty (74%) of 27 subjects in the HECTOROL capsules group achieved mean plasma intact PTH suppression of ≥30% from baseline for the last four weeks of treatment, whereas two (7%) of the 28 subjects treated with placebo achieved this level of intact PTH suppression.
Although direct studies on the FIFA 11+ Kids Training Protocol specifically for young female volleyball players are scarce, the program's principles are anticipated to enhance motor skills and physical performance. This study seeks to investigate the potential benefits of applying the FIFA 11+ principles, along with existing insights into motor skills and physical performance in volleyball, to young female players. The objective is to assess how the FIFA 11+ Kids Training Protocol affects motor competence and physical performance. This research aspect is expected to contribute innovative findings to existing literature. The study aimed to determine the effects of the FIFA 11+Kids warm-up program and standard warm-up program on motor competence and physical performance elements of young female volleyball players. A total of 34 volleyball players will complete all the measurement and exercise processes and participate in the post-tests. The experimental design involved participants being randomly assigned to exercise (EG; n=15) and control (CG; n=19) groups. In the first session, anthropometric measurements, including height and body weight, will be measured. Following that, motor competence tests, namely balancing backward, jumping sideways, moving sideways, and eye-hand coordination tests (KTK3+), were measured sequentially. On the second session, physical and functional tests were conducted. These included balance performance measurements, agility test (pro-agility), vertical jump test (countermovement jump test), and functional movement screen (FMS) test. The two-way analysis of variance will be conducted to determine whether being in the exercise group had a significant effect on test scores for mixed measurements, the group-time interaction showed that the exercise group's score increase was significantly higher than that of the control group in dynamic balance, KTK balancing backward and KTK movie sideways parameters
A water swellable cross-linked elastomer and method of preparation is provided. The elastomer can advantageously be included in skin treatment compositions. Swellable elastomers in accordance with the invention are particularly well suited for inclusion in skin tightening cosmetic products. The elastomers can be formulated to form a film. When applied to skin, an elastomer in accordance with preferred embodiments of the invention can adhere to the skin and shrink as it dries. This can provide a skin tightening, lifting and wrinkle smoothening effect upon drying. This effect can temporarily mask the appearance of wrinkles.
Vaccine for stimulating or enhancing in a subject to whom the vaccine is administered, production of antibodies directed against GM2. The vaccine comprises an amount of purified GM2 effective to stimulate or enhance antibody production in the subject, an effective amount of a microbial adjuvant and a pharmaceutically acceptable carrier. This invention also provides a method for stimulating or enhancing in a subject production of antibodies directed against GM2. The method comprises administering to the subject an effective dose of the vaccine of this invention. The microbial adjuvant may be bacillus Calmette-Guerin or Salmonella minnesota R595. This invention further provides a method for treating cancer in a subject affected with cancer. The method comprises administering to the subject an effective dose of the vaccine of this invention. Finally, this invention provides a method for preventing cancer in a subject affected with cancer. The method comprises administering to the subject an effective dose of the vaccine of this invention.
Dysregulation of long non-coding RNAs (lncRNAs) is associated with the tumorigenesis and ferroptosis of non-small cell lung cancer (NSCLC). BBOX1 antisense RNA 1 (BBOX1-AS1) functions as an oncogenic driver in NSCLC. Here, we aim to investigate the regulation effect and underlying mechanism of BBOX1-AS1 in NSCLC progression and ferroptosis. RNA expression was detected by quantitative real-time PCR (qRT-PCR), and protein expression was measured by immunoblotting. Cell growth was assessed by CCK-8 and colony formation assays. Transwell assay was applied to evaluate cell invasion and migration. RNA pull-down and dual-luciferase reporter assays were applied to verify the relationship between miR-326 and BBOX1-AS1 or prominin 2 (PROM2). The role of BBOX1-AS1 in NSCLC tumorigenicity was also analyzed by xenograft assays. Silencing BBOX1-AS1 or PROM2 impeded NSCLC cell growth, migration, and invasion. Silencing BBOX1-AS1 induced cell apoptosis and ferroptosis. BBOX1-AS1 up-regulated PROM2 expression, and re-expression of PROM2 reversed the effects of BBOX1-AS1 depletion on cell malignant phenotypes and ferroptosis. BBOX1-AS1 post-transcriptionally modulated PROM2 expression by sponging miR-326. MiR-326 was validated as a mediator of BBOX1-AS1 in regulating NSCLC cell malignant phenotypes and ferroptosis. Additionally, BBOX1-AS1 deficiency in vivo resulted in the suppression of xenograft tumor growth. Together, our study defines a novel BBOX1-AS1/miR-326/PROM2 axis in regulating NSCLC malignant progression and ferroptosis, offering new evidence for the oncogenic role of BBOX1-AS1 in NSCLC. These findings may provide a basis for the future usage of targeting BBOX1-AS1 in NSCLC treatment.